Cuatrecasas advised Columbus Venture Partners and Mérieux Equity Partners on their participation as co-lead investors in Ona Therapeutics Series B financing. Ona Therapeutics is a pioneering biopharm...
The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life...
The total planned investment for the development is around €80 million, with the asset expected to be partially operational at the beginning of 2027. This financing represents one of the most signif...
Visium has grown to a team of 100 AI experts across Europe and has delivered more than 250 AI and data solutions for global leaders in life sciences, specialty chemicals and other regulated industries...
Sermes CRO is a Spanish contract research organization (CRO) with 29 years of experience, dedicated to optimizing clinical research processes for pharmaceutical and biotechnology companies, as well as...
Syngoi is a Contract Development and Manufacturing Organisation (CDMO) specialising in synthetic DNA for advanced therapies, a critical component for therapeutic applications such as mRNA vaccines, ge...
Syngoi Technologies has developed in recent years its own enzymatic synthetic DNA platform, designed to address one of the key structural challenges in the gene and cell therapy industry: the efficien...
The company has developed an advanced computational platform, combined with high-throughput experimentation, that uses proprietary methods to design multifunctional de novo proteins. These proteins, b...
Innvierte SICC of CDTI Innovación invests in Integra Therapeutics, together with three co-investors, to develop a gene-editing platform for the treatment of oncological, autoimmune, and genetic disea...
The Series B extension financing was led by Bpifrance and joined by all existing shareholders, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...
Buenavista Equity Partners, through its specialized fund BV Healthcare Growth Innvierte I (BHG I) created in collaboration with Columbus Venture Partners, has announced its entry into the shareholding...
The funds will be used to incorporate new advances into the FiCAT gene writing platform, validate various next generation CAR-T therapies in the preclinical phase and expand the FiCAT cell engineering...